A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
Xuejun WenChangrong ShiXinying ZengLiang ZhaoLanlin YaoZhida LiuLixia FengDeliang ZhangJinxiong HuangYesen LiQin LinHaojun ChenRongqiang ZhuangXiaoyuan Shawn ChenXianzhong ZhangZhide GuoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In summary, this promising paradigm has the potential to expand the traditional tumor theranostics. 2-[18F]FDG-based ICB immunotherapy is highly significant in enhancing antitumor effect. A research of 2-[18F]FDG-based ICB immunotherapy has been proposed to enhance the antitumor effect.